Compliance Alerts

Representative actively promoted Clarovexa for primary biliary cholangitis (PBC), which is not an approved indication. Clarovexa is only approved for autoimmune hepatitis. The representative referenced anecdotal physician feedback for the off-label use and offered to share case reports supporting it.

Representative failed to provide fair balance when discussing Clarovexa's safety profile. Used vague, minimizing language such as 'excellent tolerability' and 'minimal side effects' without citing specific adverse event rates. Dismissed class-level cardiovascular safety concerns with 'I wouldn't worry about the cardiovascular risks with this one' without referencing prescribing information.

Case manager discussed protected health information including prescription details, diagnosis, and physician name while a third party (patient's daughter Karen) was on the call without first obtaining and documenting verbal consent from the patient. Additionally, collected PII (date of birth and partial SSN) while the unauthorized third party was present.

MSL made speculative claims about Veloratine's potential cardioprotective effects and benefits for HFpEF patients that are not supported by approved labeling or published peer-reviewed data. The use of 'we believe' implies a company-endorsed position on an unapproved benefit, which could be interpreted as pre-promotional activity for an investigational use.

Interaction documentation was submitted 48 hours after the call, exceeding the 24-hour documentation window required by company SOP. All content was accurate and complete, but the late submission creates a compliance documentation gap.